Stockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019 AusBiotech event in Melbourne.

In this episode Tim chats with Steven Yatomi-Clarke, CEO and managing director of Prescient Therapeutics (ASX:PTX).

Prescient Therapeutics is a Melbourne-based, clinical stage immune-oncology company that’s targeting specific mutations that cause cancers.

It’s got two candidates on the go, PTX 100 and PTX 200 and they both have novel mechanisms of action.

In particular, Prescient is targeting a mutant pathway called Ras, which has been difficult to access with traditional cancer therapies.

So tune in to hear the pair discuss Australia’s biotech performance on how Aussie health stocks are performing internationally and Prescient’s cancer-blocking innovation.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!